CN114887503B - Mixed matrix hollow fiber oxygenation membrane based on framework material and preparation method thereof - Google Patents
Mixed matrix hollow fiber oxygenation membrane based on framework material and preparation method thereof Download PDFInfo
- Publication number
- CN114887503B CN114887503B CN202210512054.0A CN202210512054A CN114887503B CN 114887503 B CN114887503 B CN 114887503B CN 202210512054 A CN202210512054 A CN 202210512054A CN 114887503 B CN114887503 B CN 114887503B
- Authority
- CN
- China
- Prior art keywords
- hollow fiber
- membrane
- mixed matrix
- framework material
- oxygenation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 66
- 239000000463 material Substances 0.000 title claims abstract description 51
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 39
- 238000006213 oxygenation reaction Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000011159 matrix material Substances 0.000 title claims abstract description 20
- 239000002904 solvent Substances 0.000 claims abstract description 29
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 238000005266 casting Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000011116 polymethylpentene Substances 0.000 claims abstract description 10
- 229920000306 polymethylpentene Polymers 0.000 claims abstract description 10
- 238000005303 weighing Methods 0.000 claims abstract description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 28
- -1 polytetrafluoroethylene Polymers 0.000 claims description 22
- 239000013384 organic framework Substances 0.000 claims description 21
- 238000009987 spinning Methods 0.000 claims description 20
- 229920001955 polyphenylene ether Polymers 0.000 claims description 15
- 238000005345 coagulation Methods 0.000 claims description 12
- 230000015271 coagulation Effects 0.000 claims description 12
- 239000004014 plasticizer Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000013310 covalent-organic framework Substances 0.000 claims description 4
- 239000012621 metal-organic framework Substances 0.000 claims description 4
- 238000007872 degassing Methods 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002033 PVDF binder Substances 0.000 claims description 2
- 239000004695 Polyether sulfone Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims description 2
- ZFMQKOWCDKKBIF-UHFFFAOYSA-N bis(3,5-difluorophenyl)phosphane Chemical compound FC1=CC(F)=CC(PC=2C=C(F)C=C(F)C=2)=C1 ZFMQKOWCDKKBIF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- 229920006393 polyether sulfone Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- WWXUGNUFCNYMFK-UHFFFAOYSA-N Acetyl citrate Chemical compound CC(=O)OC(=O)CC(O)(C(O)=O)CC(O)=O WWXUGNUFCNYMFK-UHFFFAOYSA-N 0.000 claims 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 abstract description 13
- 239000004941 mixed matrix membrane Substances 0.000 abstract description 12
- 230000035699 permeability Effects 0.000 abstract description 12
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 125000000524 functional group Chemical group 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 238000005191 phase separation Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 28
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- 229910002092 carbon dioxide Inorganic materials 0.000 description 14
- 239000001569 carbon dioxide Substances 0.000 description 14
- 239000007789 gas Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 101100457407 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mmm-1 gene Proteins 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002145 thermally induced phase separation Methods 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013354 porous framework Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- WDRCVXGINNJWPH-UHFFFAOYSA-N tris(6-methylheptyl) benzene-1,2,4-tricarboxylate Chemical compound CC(C)CCCCCOC(=O)C1=CC=C(C(=O)OCCCCCC(C)C)C(C(=O)OCCCCCC(C)C)=C1 WDRCVXGINNJWPH-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/72—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of the groups B01D71/46 - B01D71/70 and B01D71/701 - B01D71/702
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0011—Casting solutions therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0013—Casting processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/14—Dynamic membranes
- B01D69/141—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02C—CAPTURE, STORAGE, SEQUESTRATION OR DISPOSAL OF GREENHOUSE GASES [GHG]
- Y02C20/00—Capture or disposal of greenhouse gases
- Y02C20/40—Capture or disposal of greenhouse gases of CO2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W10/00—Technologies for wastewater treatment
- Y02W10/10—Biological treatment of water, waste water, or sewage
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
技术领域Technical Field
本发明属于膜技术领域,具体涉及一种基于框架材料的混合基质中空纤维氧合膜的应用。The invention belongs to the field of membrane technology, and in particular relates to an application of a mixed matrix hollow fiber oxygenation membrane based on a frame material.
背景技术Background technique
体外膜式氧合器是一种使静脉血富含氧气去除其中二氧化碳,可暂时代替人体心肺功能的医疗设备,广泛应用于肺移植、心脏手术及严重呼吸衰竭患者的救治。而氧合膜是其核心部件,氧合膜的透气性、血液相容性、抗润湿能力将直接影响氧合器的性能。Extracorporeal membrane oxygenator is a medical device that enriches venous blood with oxygen and removes carbon dioxide from it, which can temporarily replace the human heart and lung function. It is widely used in lung transplantation, heart surgery and the treatment of patients with severe respiratory failure. The oxygenation membrane is its core component. The permeability, blood compatibility and anti-wetting ability of the oxygenation membrane will directly affect the performance of the oxygenator.
氧合膜与气体分离膜没有本质上的区别,主要区别在于氧合膜侧重氧气和二氧化碳的渗透性,气体分离膜注重对目标气体的选择性和分离效率。通过将聚合物与框架材料共混制备的混合基质膜在气体分离领域展现出强大的性能。框架材料具有多孔结构和很大的比表面积,广泛应用于气体的传输和分离,金属有机框架(MOF)、共价有机框架(COF)是最为常见的两种,氢键有机框架(HOF)是一类新型的由有机构筑单元通过氢键结合形成的多孔框架材料,其不含有金属离子具有更好的生物相容性和低细胞毒性。框架材料本身的多孔结构有利于氧气和二氧化碳的渗透,而且特定的基团使框架材料孔道具有极性,将与电四极矩的二氧化碳产生相互作用,吸附二氧化碳形成二氧化碳的高速传输通道。There is no essential difference between oxygenation membranes and gas separation membranes. The main difference is that oxygenation membranes focus on the permeability of oxygen and carbon dioxide, while gas separation membranes focus on the selectivity and separation efficiency of the target gas. Mixed matrix membranes prepared by blending polymers with framework materials have shown strong performance in the field of gas separation. Framework materials have porous structures and large specific surface areas and are widely used in gas transmission and separation. Metal organic frameworks (MOFs) and covalent organic frameworks (COFs) are the two most common types. Hydrogen bonded organic frameworks (HOFs) are a new type of porous framework material formed by organic building units through hydrogen bonding. They do not contain metal ions and have better biocompatibility and low cytotoxicity. The porous structure of the framework material itself is conducive to the permeation of oxygen and carbon dioxide, and specific groups make the pores of the framework material polar, which will interact with the electric quadrupole moment of carbon dioxide and adsorb carbon dioxide to form a high-speed transmission channel for carbon dioxide.
当前商用氧合膜中聚(4-甲基-1-戊烯)中空纤维膜最具优势。聚(4-甲基-1-戊烯)中空纤维膜具有多孔海绵状主体结构和致密皮层,不易发生血浆渗漏但气体渗透性能相对其他材料较差,而且原材料聚(4-甲基-1-戊烯)采购困难,聚(4-甲基-1-戊烯)其晶区、非晶区密度一样,结晶规律不一样、晶区不规则等聚合物特性导致其膜结构调控困难,热致相分离法(TIPS)生产工艺复杂,成膜过程难以控制,而且目前聚(4-甲基-1-戊烯)中空纤维膜制备技术被3M公司垄断。Among the current commercial oxygenation membranes, poly(4-methyl-1-pentene) hollow fiber membranes have the most advantages. Poly(4-methyl-1-pentene) hollow fiber membranes have a porous sponge-like main structure and a dense cortex, which is not prone to plasma leakage, but the gas permeability is relatively poor compared to other materials. In addition, the raw material poly(4-methyl-1-pentene) is difficult to purchase. The polymer characteristics of poly(4-methyl-1-pentene) such as the same density in the crystalline and amorphous regions, different crystallization rules, and irregular crystalline regions make it difficult to regulate its membrane structure. The thermally induced phase separation (TIPS) production process is complex, and the membrane formation process is difficult to control. In addition, the preparation technology of poly(4-methyl-1-pentene) hollow fiber membranes is currently monopolized by 3M.
因此针对当前商用氧合膜存在的气体渗透性相对较差、制备困难、生产技术被垄断的问题,本发明将框架材料与适宜的聚合物共混后NIPS法制备混合基质膜,将有望同时解决这些问题,促进氧合膜材料领域的发展。Therefore, in view of the problems of relatively poor gas permeability, difficult preparation and monopoly of production technology in current commercial oxygenation membranes, the present invention prepares mixed matrix membranes by the NIPS method after blending the framework material with a suitable polymer, which is expected to solve these problems at the same time and promote the development of the field of oxygenation membrane materials.
发明内容Summary of the invention
本发明通过将框架材料与聚合物共混并用NIPS法成膜,制备了一种既具有较好氧气和二氧化碳渗透性能又工艺简单的混合基质中空纤维氧合膜。The invention prepares a mixed matrix hollow fiber oxygenation membrane which has good oxygen and carbon dioxide permeability and simple process by blending a frame material with a polymer and forming a membrane by a NIPS method.
本发明提出一种基于框架材料的混合基质中空纤维氧合膜及其制备方法,其特征在于,包括如下步骤:The present invention provides a mixed matrix hollow fiber oxygenation membrane based on a frame material and a preparation method thereof, which is characterized by comprising the following steps:
(1)按照配方称取物料,包括聚合物、溶剂1、增塑剂、框架材料;(1) Weighing materials according to the formula, including polymer, solvent 1, plasticizer, and frame material;
(2)先加入部分物料包括溶剂1、增塑剂和框架材料,进行超声处理直至分散均匀,之后加入聚合物加热搅拌静置脱泡制备混合基质膜铸膜液;(2) first adding some materials including solvent 1, plasticizer and frame material, and performing ultrasonic treatment until they are evenly dispersed, then adding polymer, heating, stirring, standing and degassing to prepare mixed matrix membrane casting solution;
(3)选择合适尺寸喷丝头进行纺丝,纺丝原液导入凝固浴溶剂2,通过NIPS法进行混合基质中空纤维膜成膜。(3) Select a spinneret of appropriate size for spinning, introduce the spinning solution into the coagulation bath solvent 2, and form a mixed matrix hollow fiber membrane by the NIPS method.
进一步地,所述步骤(1)中,聚合物20-25%,溶剂70-76%,增塑剂4-5%,框架材料添加量为聚合物质量的1-7%,增塑剂的加入使膜具备一定的柔韧性满足氧合膜的使用要求。Furthermore, in the step (1), the polymer is 20-25%, the solvent is 70-76%, the plasticizer is 4-5%, and the frame material addition amount is 1-7% of the polymer mass. The addition of the plasticizer makes the membrane have a certain flexibility to meet the use requirements of the oxygenated membrane.
进一步地,所述步骤(1)中,所述的框架材料为氢键有机框架材料、共价有机框架材料、金属有机框架材料中的一种或多种;所述的增塑剂为柠檬酸三丁酯、乙酰柠檬酸三丁酯、邻苯二甲酸二辛酯、邻苯二甲酸二异壬酯、己二酸二辛酯、偏苯三甲酸三异辛酯、环氧大豆油中的一种或多种;所述的聚合物为聚苯醚、聚偏氟乙烯、聚四氟乙烯、聚砜、聚醚砜、聚丙烯、聚(4-甲基-1-戊烯)中的一种或多种;溶剂1为聚合物的良溶剂氯仿、苯、甲苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮中的一种或多种。Furthermore, in step (1), the framework material is one or more of a hydrogen-bonded organic framework material, a covalent organic framework material, and a metal-organic framework material; the plasticizer is one or more of tributyl citrate, acetyl tributyl citrate, dioctyl phthalate, diisononyl phthalate, dioctyl adipate, triisooctyl trimellitate, and epoxy soybean oil; the polymer is one or more of polyphenylene ether, polyvinylidene fluoride, polytetrafluoroethylene, polysulfone, polyethersulfone, polypropylene, and poly(4-methyl-1-pentene); and the solvent 1 is one or more of a good solvent for the polymer, including chloroform, benzene, toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone.
进一步地,所述步骤(2)中,将框架材料和增塑剂加入到溶剂1中,超声处理1h待框架材料分散均匀后加入聚合物,加热至80℃搅拌8h使聚合物充分溶解避免小颗粒的出现,停止搅拌降温至60℃静置脱泡6h后得到铸膜液。Furthermore, in the step (2), the framework material and the plasticizer are added to the solvent 1, and the polymer is added after the framework material is evenly dispersed after ultrasonic treatment for 1 hour, and the mixture is heated to 80°C and stirred for 8 hours to fully dissolve the polymer and avoid the appearance of small particles. Stirring is stopped, the temperature is lowered to 60°C, and the mixture is allowed to stand for degassing for 6 hours to obtain the casting solution.
进一步地,所述步骤(3)中,所述的溶剂2为可与溶剂1互溶且不溶聚合物的溶剂,水、乙醇、甲醇中的一种或多种。Furthermore, in step (3), the solvent 2 is a solvent that is miscible with the solvent 1 and insoluble in the polymer, and is one or more of water, ethanol, and methanol.
进一步地,所述步骤(3)中,混合基质中空纤维膜通过NIPS法成膜,铸膜液恒温60℃下加入纺丝机中,环状喷嘴的吐出的纺丝原液导入溶剂2凝固浴。Furthermore, in the step (3), the mixed matrix hollow fiber membrane is formed by the NIPS method, the casting solution is added to the spinning machine at a constant temperature of 60°C, and the spinning solution discharged from the annular nozzle is introduced into the solvent 2 coagulation bath.
进一步地,所述步骤(3)中,喷丝头与溶剂2凝固浴液面之间的距离为10cm-15cm,纺丝速度为2-5m/min。Furthermore, in the step (3), the distance between the spinneret and the surface of the coagulation bath of solvent 2 is 10 cm-15 cm, and the spinning speed is 2-5 m/min.
进一步地,所述步骤(3)中,混合基质中空纤维膜外径为300-400μm,壁厚50-100μm,横截面呈多孔疏松结构。Furthermore, in step (3), the outer diameter of the mixed matrix hollow fiber membrane is 300-400 μm, the wall thickness is 50-100 μm, and the cross section presents a porous loose structure.
有益效果Beneficial Effects
(1)本发明通过加入框架材料来制备混合基质中空纤维氧合膜,首先框架材料具有多孔结构的特点,框架材料引入后其内部孔道将为氧合过程中氧气和二氧化碳的传输提供额外的传输通道,而且内部孔道表面所含有的三嗪基团、羧基、苯环等基团会与电四极矩的二氧化碳产生极性相互作用,吸附二氧化碳形成高速的二氧化碳传输通道,极大提高氧合膜的气体渗透率。其次,框架材料表面具有有机官能团从而与有机聚合物具有较好界面相容性,避免了缺陷和团聚的产生。(1) The present invention prepares a mixed matrix hollow fiber oxygenation membrane by adding a framework material. First, the framework material has the characteristics of a porous structure. After the framework material is introduced, its internal pores will provide additional transmission channels for the transmission of oxygen and carbon dioxide during the oxygenation process. In addition, the triazine groups, carboxyl groups, benzene rings and other groups contained on the surface of the internal pores will produce polar interactions with the carbon dioxide of the electric quadrupole moment, adsorb carbon dioxide to form a high-speed carbon dioxide transmission channel, and greatly improve the gas permeability of the oxygenation membrane. Secondly, the surface of the framework material has organic functional groups, so it has good interface compatibility with organic polymers, avoiding the generation of defects and agglomerations.
(2)聚(4-甲基-1-戊烯)的晶区、非晶区密度一样,且成孔尺度很小、结晶规律不一样、晶区不规则、晶粒尺寸和形态比较特殊,导致需要获得疏松膜结构保证较好气体渗透性的聚(4- 甲基-1-戊烯)中空纤维膜制备过程难以控制,生产难度很大。相比于此,本发明通过简单的共混方法制备混合基质膜的途径来提高氧合膜的气体渗透性,并且用NIPS法进行成膜,极大减小制备难度,避免了复杂的制备工艺。(2) The density of the crystalline and amorphous regions of poly(4-methyl-1-pentene) is the same, and the pore size is very small, the crystallization law is different, the crystalline region is irregular, and the grain size and morphology are relatively special, which results in the difficulty in controlling the preparation process of the poly(4-methyl-1-pentene) hollow fiber membrane, which needs to obtain a loose membrane structure to ensure good gas permeability, and the production is very difficult. In contrast, the present invention improves the gas permeability of the oxygenated membrane by preparing a mixed matrix membrane through a simple blending method, and uses the NIPS method for membrane formation, which greatly reduces the difficulty of preparation and avoids complex preparation processes.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1(a)为添加氢键有机框架PFC-11前后的中空纤维氧合膜氧气气液传输测试结果;图1 (b) 为添加氢键有机框架PFC-11前后的中空纤维氧合膜氧气气液传输速率对比。Figure 1 (a) shows the test results of oxygen gas-liquid transmission of hollow fiber oxygenation membrane before and after adding hydrogen bond organic framework PFC-11; Figure 1 (b) shows the comparison of oxygen gas-liquid transmission rate of hollow fiber oxygenation membrane before and after adding hydrogen bond organic framework PFC-11.
图2为添加氢键有机框架PFC-11前后的中空纤维氧合膜氧气和二氧化碳渗透性能对比。Figure 2 is a comparison of the oxygen and carbon dioxide permeation performance of the hollow fiber oxygenation membrane before and after the addition of the hydrogen-bonded organic framework PFC-11.
具体实施方式Detailed ways
实施例1 MMM-1氧合膜的制备Example 1 Preparation of MMM-1 oxygenation membrane
物料配方:Material formula:
聚苯醚和甲苯的比例为1∶3,柠檬酸三正丁酯和氢键有机框架PFC-11分别为聚合物质量的24%和1%。按比例称取20g聚苯醚、60g甲苯、4.8g柠檬酸三正丁酯、200mg氢键有机框架PFC-11。The ratio of polyphenylene ether to toluene is 1:3, tri-n-butyl citrate and hydrogen-bonded organic framework PFC-11 are 24% and 1% of the polymer mass respectively. 20g polyphenylene ether, 60g toluene, 4.8g tri-n-butyl citrate and 200mg hydrogen-bonded organic framework PFC-11 are weighed in proportion.
铸膜液的制备:Preparation of casting solution:
先将称取好甲苯、柠檬酸三正丁酯和氢键有机框架PFC-11加入100mL三口烧瓶中后,超声处理直至氢键有机框架PFC-11分散均匀,得到白色悬浊液。将聚苯醚加入悬浊液中,并在80℃加热下搅拌8h。搅拌好的铸膜液降温至60℃静置6h,准备用于制备中空纤维膜。First, weigh toluene, tri-n-butyl citrate and hydrogen-bonded organic framework PFC-11 and add them into a 100 mL three-necked flask, and then ultrasonicate until the hydrogen-bonded organic framework PFC-11 is evenly dispersed to obtain a white suspension. Add polyphenylene ether to the suspension and stir at 80°C for 8 hours. Cool the stirred casting solution to 60°C and let it stand for 6 hours to prepare the hollow fiber membrane.
混合基质膜的制备:Preparation of mixed matrix membranes:
铸膜液恒温60℃下加入纺丝机中,选择环状喷丝头内径为250μm,外径为450μm,纺丝速度为2m/min。环状喷丝头吐出的纺丝原液导入乙醇凝固浴中进行溶剂交换,喷丝头与的乙醇凝固浴液面之间的距离为10cm,溶剂交换后的中空纤维膜在乙醇中浸泡2-3天确保除去甲苯,得到混合基质中空纤维氧合膜,命名为MMM-1。The casting solution was added to the spinning machine at a constant temperature of 60°C, and the inner diameter of the annular spinneret was selected to be 250 μm, the outer diameter was 450 μm, and the spinning speed was 2 m/min. The spinning solution spitted out by the annular spinneret was introduced into the ethanol coagulation bath for solvent exchange, and the distance between the spinneret and the surface of the ethanol coagulation bath was 10 cm. The hollow fiber membrane after solvent exchange was soaked in ethanol for 2-3 days to ensure the removal of toluene, and a mixed matrix hollow fiber oxygenation membrane was obtained, named MMM-1.
实施例2 MMM-2氧合膜的制备Example 2 Preparation of MMM-2 oxygenation membrane
物料配方:Material formula:
聚苯醚和甲苯的比例为1∶3,柠檬酸三正丁酯和氢键有机框架PFC-11分别为聚合物质量的24%和2%。按比例称取20g聚苯醚、60g甲苯、4.8g柠檬酸三正丁酯、400mg氢键有机框架PFC-11。The ratio of polyphenylene ether to toluene is 1:3, tri-n-butyl citrate and hydrogen-bonded organic framework PFC-11 are 24% and 2% of the polymer mass respectively. 20g polyphenylene ether, 60g toluene, 4.8g tri-n-butyl citrate and 400mg hydrogen-bonded organic framework PFC-11 are weighed in proportion.
铸膜液的制备:Preparation of casting solution:
先将称取好甲苯、柠檬酸三正丁酯和氢键有机框架PFC-11加入100mL三口烧瓶中后,超声处理直至氢键有机框架PFC-11分散均匀,得到白色悬浊液。将聚苯醚加入悬浊液中,并在80℃加热下搅拌8h。搅拌好的铸膜液降温至60℃静置6h,准备用于制备中空纤维膜。First, weigh toluene, tri-n-butyl citrate and hydrogen-bonded organic framework PFC-11 and add them into a 100 mL three-necked flask, and then ultrasonicate until the hydrogen-bonded organic framework PFC-11 is evenly dispersed to obtain a white suspension. Add polyphenylene ether to the suspension and stir at 80°C for 8 hours. Cool the stirred casting solution to 60°C and let it stand for 6 hours to prepare the hollow fiber membrane.
混合基质膜的制备:Preparation of mixed matrix membranes:
铸膜液恒温60℃下加入纺丝机中,选择环状喷丝头内径为250μm,外径为450μm,纺丝速度为2m/min。环状喷丝头吐出的纺丝原液导入乙醇凝固浴中进行溶剂交换,喷丝头与的乙醇凝固浴液面之间的距离为10cm,溶剂交换后的中空纤维膜在乙醇中浸泡2-3天确保除去甲苯,得到混合基质中空纤维氧合膜,命名为MMM-2。The casting solution was added to the spinning machine at a constant temperature of 60°C, and the inner diameter of the annular spinneret was selected to be 250 μm, the outer diameter was 450 μm, and the spinning speed was 2 m/min. The spinning solution spitted out by the annular spinneret was introduced into an ethanol coagulation bath for solvent exchange, and the distance between the spinneret and the surface of the ethanol coagulation bath was 10 cm. The hollow fiber membrane after solvent exchange was soaked in ethanol for 2-3 days to ensure the removal of toluene, and a mixed matrix hollow fiber oxygenation membrane was obtained, named MMM-2.
实施例3 MMM-3氧合膜的制备Example 3 Preparation of MMM-3 oxygenated membrane
物料配方:Material formula:
聚苯醚和甲苯的比例为1∶3,柠檬酸三正丁酯和氢键有机框架PFC-11分别为聚合物质量的24%和3%。按比例称取20g聚苯醚、60g甲苯、4.8g柠檬酸三正丁酯、600mg氢键有机框架PFC-11。The ratio of polyphenylene ether to toluene is 1:3, tri-n-butyl citrate and hydrogen-bonded organic framework PFC-11 are 24% and 3% of the polymer mass respectively. 20g polyphenylene ether, 60g toluene, 4.8g tri-n-butyl citrate and 600mg hydrogen-bonded organic framework PFC-11 are weighed in proportion.
铸膜液的制备:Preparation of casting solution:
先将称取好甲苯、柠檬酸三正丁酯和氢键有机框架PFC-11加入100mL三口烧瓶中后,超声处理直至氢键有机框架PFC-11分散均匀,得到白色悬浊液。将聚苯醚加入悬浊液中,并在80℃加热下搅拌8h。搅拌好的铸膜液降温至60℃静置6h,准备用于制备中空纤维膜。First, weigh toluene, tri-n-butyl citrate and hydrogen-bonded organic framework PFC-11 and add them into a 100 mL three-necked flask, and then ultrasonicate until the hydrogen-bonded organic framework PFC-11 is evenly dispersed to obtain a white suspension. Add polyphenylene ether to the suspension and stir at 80°C for 8 hours. Cool the stirred casting solution to 60°C and let it stand for 6 hours to prepare the hollow fiber membrane.
混合基质膜的制备:Preparation of mixed matrix membranes:
铸膜液恒温60℃下加入纺丝机中,选择环状喷丝头内径为250μm,外径为450μm,纺丝速度为2m/min。环状喷丝头吐出的纺丝原液导入乙醇凝固浴中进行溶剂交换,喷丝头与的乙醇凝固浴液面之间的距离为10cm,溶剂交换后的中空纤维膜在乙醇中浸泡2-3天确保除去甲苯,得到混合基质中空纤维氧合膜,命名为MMM-3。The casting solution was added to the spinning machine at a constant temperature of 60°C, and the inner diameter of the annular spinneret was selected to be 250 μm, the outer diameter was 450 μm, and the spinning speed was 2 m/min. The spinning solution spitted out by the annular spinneret was introduced into the ethanol coagulation bath for solvent exchange, and the distance between the spinneret and the surface of the ethanol coagulation bath was 10 cm. The hollow fiber membrane after solvent exchange was soaked in ethanol for 2-3 days to ensure the removal of toluene, and a mixed matrix hollow fiber oxygenation membrane was obtained, named MMM-3.
对照例1 MMM-0氧合膜的制备Comparative Example 1 Preparation of MMM-0 oxygenation membrane
物料配方:Material formula:
聚苯醚和甲苯的比例为1∶3,柠檬酸三正丁酯为聚合物质量的24%。按比例称取20g 聚苯醚、60g甲苯、4.8g柠檬酸三正丁酯。The ratio of polyphenylene ether to toluene is 1:3, and tri-n-butyl citrate accounts for 24% of the polymer mass. 20 g of polyphenylene ether, 60 g of toluene, and 4.8 g of tri-n-butyl citrate are weighed in proportion.
铸膜液的制备:Preparation of casting solution:
先将称取好甲苯、柠檬酸三正丁酯和聚苯醚加入100mL三口烧瓶中,并在80℃加热下搅拌8h。搅拌好的铸膜液降温至60℃静置6h,准备用于制备中空纤维膜。First, weigh toluene, tri-n-butyl citrate and polyphenylene ether into a 100 mL three-necked flask and stir at 80°C for 8 hours. The stirred casting solution is cooled to 60°C and allowed to stand for 6 hours to prepare the hollow fiber membrane.
混合基质膜的制备:Preparation of mixed matrix membranes:
铸膜液恒温60℃下加入纺丝机中,选择环状喷丝头内径为250μm,外径为450μm,纺丝速度为2m/min。环状喷丝头吐出的纺丝原液导入乙醇凝固浴中进行溶剂交换,喷丝头与的乙醇凝固浴液面之间的距离为10cm,溶剂交换后的中空纤维膜在乙醇中浸泡2-3天确保除去甲苯,得到中空纤维氧合膜,命名为MMM-0。The casting solution was added to the spinning machine at a constant temperature of 60°C, and the inner diameter of the annular spinneret was selected to be 250μm, the outer diameter was 450μm, and the spinning speed was 2m/min. The spinning solution spitted out by the annular spinneret was introduced into the ethanol coagulation bath for solvent exchange, and the distance between the spinneret and the surface of the ethanol coagulation bath was 10cm. The hollow fiber membrane after solvent exchange was soaked in ethanol for 2-3 days to ensure the removal of toluene, and a hollow fiber oxygenation membrane was obtained, which was named MMM-0.
试验例1混合基质膜中空纤维氧合膜氧气气液传输性能测试Test Example 1 Test on oxygen gas-liquid transmission performance of mixed matrix membrane hollow fiber oxygenation membrane
使用去离子水模拟血液测试了MMM-0、MMM-1、MMM-2、MMM-3的氧气气液传输性能。参阅图1(a),图中折线体现了模拟液到达氧饱和的快慢,添加了氢键有机框架PFC-11的混合基质膜氧气传输明显优于未添加的纯聚苯醚中空纤维膜,其中MMM-3具有最佳的效果。参阅图1(b),未添加氢键有机框架PFC-11的MMM-0其氧气气液传输能力仅为22.4 mL/(min·m2),MMM-3的氧气气液传输能力提高到35.2mL/(min·m2),提高57.1%。The oxygen gas-liquid transmission performance of MMM-0, MMM-1, MMM-2, and MMM-3 was tested using deionized water to simulate blood. Refer to Figure 1(a). The broken line in the figure reflects the speed at which the simulated liquid reaches oxygen saturation. The oxygen transmission of the mixed matrix membrane with the addition of hydrogen-bonded organic framework PFC-11 is significantly better than that of the pure polyphenylene ether hollow fiber membrane without the addition, among which MMM-3 has the best effect. Refer to Figure 1(b). The oxygen gas-liquid transmission capacity of MMM-0 without the addition of hydrogen-bonded organic framework PFC-11 is only 22.4 mL/(min·m 2 ), while the oxygen gas-liquid transmission capacity of MMM-3 is increased to 35.2 mL/(min·m 2 ), an increase of 57.1%.
试验例2混合基质膜中空纤维氧合膜气体渗透性能测试Test Example 2 Gas Permeability Test of Mixed Matrix Membrane Hollow Fiber Oxygenation Membrane
对MMM-0、MMM-1、MMM-2、MMM-3进行了氧气和二氧化碳气体渗透性能。参阅图 2,由图2可以看出氢键有机框架PFC-11的加入高效的提高了氧气和二氧化碳的渗透性能。对于MMM-3由MMM-0的1.62GPU提高到3.51GPU,提高116.5%The oxygen and carbon dioxide gas permeability of MMM-0, MMM-1, MMM-2, and MMM-3 was tested. See Figure 2. It can be seen from Figure 2 that the addition of the hydrogen bond organic framework PFC-11 effectively improves the oxygen and carbon dioxide permeability. For MMM-3, it increased from 1.62 GPU of MMM-0 to 3.51 GPU, an increase of 116.5%.
以上仅为本发明的较佳实施例,并不是对本发明的限制,任何本领域的技术人员可能利用上述揭示的技术内容加以变更或改进,但凡是未脱离本发明构思,依据本发明技术实质对以上实施例所作的任何修改,等同变化与改进,仍属于本发明的保护范围。The above are only preferred embodiments of the present invention and are not limitations of the present invention. Any technician in the field may use the technical content disclosed above to make changes or improvements. However, any modifications, equivalent changes and improvements made to the above embodiments based on the technical essence of the present invention without departing from the concept of the present invention are still within the protection scope of the present invention.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210512054.0A CN114887503B (en) | 2022-05-17 | 2022-05-17 | Mixed matrix hollow fiber oxygenation membrane based on framework material and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210512054.0A CN114887503B (en) | 2022-05-17 | 2022-05-17 | Mixed matrix hollow fiber oxygenation membrane based on framework material and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114887503A CN114887503A (en) | 2022-08-12 |
CN114887503B true CN114887503B (en) | 2024-07-19 |
Family
ID=82722096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210512054.0A Active CN114887503B (en) | 2022-05-17 | 2022-05-17 | Mixed matrix hollow fiber oxygenation membrane based on framework material and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114887503B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110339596A (en) * | 2019-08-16 | 2019-10-18 | 天津工业大学 | A preparation method of oil-water separation composite membrane adding COFs |
CN114100380A (en) * | 2021-11-23 | 2022-03-01 | 天津大学 | Mixed matrix membrane with through channel structure and preparation and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4008047A (en) * | 1974-12-26 | 1977-02-15 | North Star Research Institute | Blood compatible polymers for blood oxygenation devices |
US12109549B2 (en) * | 2018-05-18 | 2024-10-08 | Research Triangle Institute | Method of making colloidal suspensions of metal organic frameworks in polymeric solutions and uses thereof |
-
2022
- 2022-05-17 CN CN202210512054.0A patent/CN114887503B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110339596A (en) * | 2019-08-16 | 2019-10-18 | 天津工业大学 | A preparation method of oil-water separation composite membrane adding COFs |
CN114100380A (en) * | 2021-11-23 | 2022-03-01 | 天津大学 | Mixed matrix membrane with through channel structure and preparation and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114887503A (en) | 2022-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116966756A (en) | Blood purifying membrane for removing proinflammatory cytokines and preparation method thereof | |
CN101837247B (en) | Liquid medicine filtering membrane and preparation method thereof | |
CN104368246A (en) | Polyacrylonitrile/cellulose acetate fiber composite hemodialysis membrane and preparation method thereof | |
CN114887503B (en) | Mixed matrix hollow fiber oxygenation membrane based on framework material and preparation method thereof | |
CN113398773B (en) | Poly (4-methyl-1-pentene) hollow fiber alloy membrane and preparation method and application thereof | |
JP5413317B2 (en) | Hollow fiber microporous membrane and membrane oxygenator incorporating the same | |
CN109316982A (en) | Heparin-like modified polyurethane/polyethersulfone blended hollow fiber membrane and preparation method thereof | |
CN112588125A (en) | Surface modified polysulfone/polyethersulfone membrane and preparation method thereof | |
US6967003B2 (en) | Artificial lung of membrane type | |
CN111773931B (en) | Hemodialysis membrane and preparation method thereof | |
CN114392655A (en) | Preparation method of hemodialysis filtration membrane | |
CN112044289B (en) | Dialysis membrane for high-efficiency hemodialysis instrument and preparation method | |
CN107899433A (en) | Polyether sulfone/sulfonated polyether sulfone doughnut blend film for haemodialysis | |
CN114749036A (en) | A kind of hollow fiber heteromembrane and its preparation method and application | |
CN117398857B (en) | Hollow fiber membrane, method for producing same, oxygenation membrane, and oxygenator | |
CN114588788B (en) | Composite fiber membrane and preparation method and application thereof | |
CN113262341B (en) | Hollow fiber membrane for extracorporeal membrane oxygenator and preparation method thereof | |
CN116262204A (en) | A kind of hollow fiber composite membrane for ECMO membrane oxygenator | |
CN114177778B (en) | Modified blood purification membrane and preparation method thereof | |
CN206008499U (en) | Fiber membrane with hollow structure for plasma separation | |
Guo et al. | Polypropylene/poly (ethylene chlorotrifluoroethylene) blend membrane for prolonged blood oxygenation | |
CN114749032B (en) | PMP hollow fiber membrane and preparation method and application thereof | |
CN114232129B (en) | Polyether sulfone fiber and preparation method and application thereof | |
CN104437137A (en) | Rare earth element containing hemodialysis membrane and preparation method thereof | |
CN116731376A (en) | Preparation of an asymmetric nanopore membrane and its application in oxygenation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |